<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00733538</url>
  </required_header>
  <id_info>
    <org_study_id>IFM-04-01</org_study_id>
    <nct_id>NCT00733538</nct_id>
  </id_info>
  <brief_title>Stage I Multiple Myeloma Treatment</brief_title>
  <acronym>IFM-01-04</acronym>
  <official_title>Stage I Multiple Myeloma Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Assessment of survival without progression of stage I MM in two groups: arm A: simple&#xD;
           survey and arm B: administration of Zoledronate.&#xD;
&#xD;
        -  Describe different progression's type noticed and define the prognosis factors of a fast&#xD;
           evolution.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      RATIONAL:&#xD;
&#xD;
      Multiple Myeloma in spite of therapy progresses mainly due to stem cell auto transplant,&#xD;
      still remain a deadly disease. About 2000 new cases are diagnosed every year in France. The&#xD;
      asymptomatic Stage I MM according to Duries and Salmon's staging are usually only watch over&#xD;
      and only treated at progression. Zoledronate is a third generation aminobiphosphonate (BP),&#xD;
      probably the most powerful among the available compounds which received market clearance&#xD;
      authorisation in MM with bone damage. During MM, bone's hyper resorption is premature.&#xD;
      Interactions exist between tumor growth and bone lyses. Zoledronate's got a proper&#xD;
      antimyeloma's action (induce plasma cells apoptosis). We propose to test the early use of&#xD;
      Zoledronate as soon as stage I MM to delay progression.&#xD;
&#xD;
      STUDY'S OBJECTIVES:&#xD;
&#xD;
        -  PRINCIPAL: Assessment of survival without progression stage I MM in two groups: A arm:&#xD;
           simple survey and B arm: administration of BP.&#xD;
&#xD;
        -  SECONDARY: Describe different progression's type noticed (bone/extra bone) and define&#xD;
           the prognosis factor of a fast stage I MM evolution (standard factors, cytogenetic 13&#xD;
           deletion, bone's restructuring strains: crosslaps, bone alkaline phosphatase), list side&#xD;
           effects.&#xD;
&#xD;
      STUDY'S KIND:&#xD;
&#xD;
      Multicenter international randomised trial, open labelled, with individual profit.&#xD;
&#xD;
      CONTRIBUTING CENTERS:&#xD;
&#xD;
      Intergroupe Francophone du Myélome's centers.&#xD;
&#xD;
      INCLUSIONS CRITERIA:&#xD;
&#xD;
      Asymptomatic stage I MM without bone's lesion on the standard radiographs.&#xD;
&#xD;
      STUDY'S MONITORING:&#xD;
&#xD;
      After checking inclusion and non inclusion specifications, the patient will be included in&#xD;
      the study and randomized (A arm or B arm) before all treatment. The randomisation will be&#xD;
      done by center and stratified according to the diagnostic date witch a year or not.&#xD;
&#xD;
        -  Arm A: simple survey as standard practice.&#xD;
&#xD;
        -  Arm B: a 15 minutes infusion of Zoledronate every month until progression or a maximum&#xD;
           of 18 infusions if no progression. The exams are the one usually defined according to&#xD;
           good clinical practices guidelines besides cytogenetic, bone's restructuring strain and&#xD;
           serum creatin dosage before each infusion in B arm.&#xD;
&#xD;
      STATISTICAL PURPOSES:&#xD;
&#xD;
      The minimum number of patients required showing a median survival time increase without&#xD;
      progression of 26 months in the control arm and 38 months in the BP arm is about 175 patients&#xD;
      in each arm for a 48 months inclusion's period, and a monitoring of 24 months after the last&#xD;
      inclusion (i.e. a study's length of 6 years).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>December 2004</start_date>
  <completion_date type="Anticipated">November 2012</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Survival without progress</measure>
    <time_frame>every month during 6 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>predictive factors of a fast evolution of multiple myeloma</measure>
    <time_frame>every month during 6 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Secondary effects of zolédronate</measure>
    <time_frame>every month during six years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Multiple Myeloma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients receiving zometa treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No treatment, just follow-up</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>zometa</intervention_name>
    <description>patients receiving treatment during their follow-up</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  stage I multiple myeloma without bones injuries&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  abnormal kidney function&#xD;
&#xD;
          -  VIH infection&#xD;
&#xD;
          -  Hepatic incapacity&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  Associate pathology&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jean-Gabriel FUZIBET, PU-PH</last_name>
    <role>Principal Investigator</role>
    <affiliation>service de médecine interne, CHU de Nice</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Medecine interne, Hôpital l'ARCHET, CHU de Nice</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <study_first_submitted>August 12, 2008</study_first_submitted>
  <study_first_submitted_qc>August 12, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2008</study_first_posted>
  <last_update_submitted>March 23, 2012</last_update_submitted>
  <last_update_submitted_qc>March 23, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 26, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zoledronic Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

